NCT07523516Not yet recruiting
Diagnostic Performance of 18F-FDG PET/CT in Detecting Distant Metastases in Breast Cancer
Diagnostic Performance of F18-FDG PET/CT in Detecting Distant Metastases in Breast Cancer
Source: ClinicalTrials.gov · Last updated 13 Apr 2026
Brief summary (registry, in English)
compare the accuracy and sensitivity of 18F FDG-PET/CT and CE-CT in detecting distant metastases in breast cancer
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 97 (estimated)
- First submitted
- 5 Apr 2026
- Start date
- Apr 2026
- Primary completion date
- Apr 2026
- Lead sponsor
- Assiut University
- NCT number
- NCT07523516
What you commit to
- Study type: Observational
- Planned participants: 97
- From Apr 2026 to the primary completion date, Apr 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Criteria the registry did not label
- Inclusion criteria:
- Patients with pathologically proven breast cancer
- Metastatic breast cancer proved by pathology or radiological modalities.
- Interval between 18F-FDG PET/CT and CE-CT from one to three weeks.
- Exclusion criteria:
- Patients with known concomitant malignancy
- Patients receive systemic treatment chemotherapy or radiotherapy between 18F-FDG PET/CT and CE-CT.
Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.